User profiles for F Carrat
 | Fabrice CarratProfessor Public health, epidemiology, biostatistics, university paris 6 Verified email at u707.jussieu.fr Cited by 29604 |
Time lines of infection and disease in human influenza: a review of volunteer challenge studies
F Carrat, E Vergu, NM Ferguson… - American journal of …, 2008 - academic.oup.com
… Defined as a temperature of 100F or 37.8C or above, fever was reported in 34.9 percent (95
percent CI: 26.7, 44.2) of infected individuals (table 4). A lower proportion of fever in …
percent CI: 26.7, 44.2) of infected individuals (table 4). A lower proportion of fever in …
Influenza vaccine: the challenge of antigenic drift
F Carrat, A Flahault - Vaccine, 2007 - Elsevier
Influenza continues to have a major worldwide impact, resulting in considerable human
suffering and economic burden. The regular recurrence of influenza epidemics is thought to be …
suffering and economic burden. The regular recurrence of influenza epidemics is thought to be …
Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure
HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Although HBV
infection can be efficiently prevented by vaccination, and treatments are available, to date …
infection can be efficiently prevented by vaccination, and treatments are available, to date …
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
Background Reports of an increased risk of lymphoproliferative disorders in patients receiving
thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a …
thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a …
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial
F Carrat, F Bani-Sadr, S Pol, E Rosenthal… - Jama, 2004 - jamanetwork.com
… Financial Disclosures: Dr Carrat has received research grants, served as a consultant for,
or has received travel expenses from Roche, GlaxoSmithKline, Chiron, Schering-Plough, and …
or has received travel expenses from Roche, GlaxoSmithKline, Chiron, Schering-Plough, and …
[HTML][HTML] Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis
…, M Rosenzwajg, F Joly, A Six, F Carrat… - … England Journal of …, 2011 - Mass Medical Soc
Background Patients with vasculitis induced by the hepatitis C virus (HCV) have reduced levels
of regulatory T cells (Tregs). Resolution of HCV infection correlates with cure of vasculitis …
of regulatory T cells (Tregs). Resolution of HCV infection correlates with cure of vasculitis …
Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 …
… Dr Carrat reported personal fees from Sanofi outside the submitted work. Dr de Lamballerie
reported grants from the French Ministry of Research and the French Institute of Health and …
reported grants from the French Ministry of Research and the French Institute of Health and …
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients
…, L Bouillet, C Arnaud, L Ades, F Carrat… - British Journal of …, 2022 - academic.oup.com
Background A new autoinflammatory syndrome related to somatic mutations of UBA1 was
recently described and called VEXAS syndrome (‘Vacuoles, E1 Enzyme, X‐linked, …
recently described and called VEXAS syndrome (‘Vacuoles, E1 Enzyme, X‐linked, …
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study
F Carrat, H Fontaine, C Dorival, M Simony, C Hezode… - The Lancet, 2019 - thelancet.com
Background Although direct-acting antivirals have been used extensively to treat patients
with chronic hepatitis C virus (HCV) infection, their clinical effectiveness has not been well …
with chronic hepatitis C virus (HCV) infection, their clinical effectiveness has not been well …
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease
L Peyrin–Biroulet, K Khosrotehrani, F Carrat… - Gastroenterology, 2011 - Elsevier
BACKGROUND & AIMS: Patients with inflammatory bowel disease (IBD) who have been
exposed to thiopurines might have an increased risk of skin cancer. We assessed this risk …
exposed to thiopurines might have an increased risk of skin cancer. We assessed this risk …